TY  - JOUR
AU  - Bowyer, S
AU  - Prithviraj, P
AU  - Lorigan, P
AU  - Larkin, J
AU  - McArthur, G
AU  - Atkinson, V
AU  - Millward, M
AU  - Khou, M
AU  - Diem, S
AU  - Ramanujam, S
AU  - Kong, B
AU  - Liniker, E
AU  - Guminski, A
AU  - Parente, P
AU  - Andrews, MC
AU  - Parakh, S
AU  - Cebon, J
AU  - Long, GV
AU  - Carlino, MS
AU  - Klein, O
Y2  - 2021/02/04
Y1  - 2016/05/10
SN  - 0007-0920
UR  - http://hdl.handle.net/11343/259450
AB  - BACKGROUND: Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy. METHODS: We retrospectively identified a cohort of 40 patients with metastatic melanoma who received single-agent anti-PD-1 therapy with pembrolizumab or nivolumab and were treated on progression with ipilimumab at a dose of 3 mg kg(-1) for a maximum of four doses. RESULTS: Ten percent of patients achieved an objective response to ipilimumab, and an additional 8% experienced prolonged (>6 months) stable disease. Thirty-five percent of patients developed grade 3-5 immune-related toxicity associated with ipilimumab therapy. The most common high-grade immune-related toxicity was diarrhoea. Three patients (7%) developed grade 3-5 pneumonitis leading to death in one patient. CONCLUSIONS: Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable to previous reports. There appears to be an increased frequency of high-grade immune-related adverse events including pneumonitis that warrants close surveillance.
LA  - English
PB  - NATURE PUBLISHING GROUP
T1  - Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
DO  - 10.1038/bjc.2016.107
IS  - British Journal of Cancer
VL  - 114
IS  - 10
SP  - 1084-1089
L1  - /bitstream/handle/11343/259450/PMC4865968.pdf?sequence=1&isAllowed=y
ER  -